B. longum CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice

ABSTRACTThe gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes mellitus (T2DM). In this study, we investigated the synergistic potential of combining the effects of Bifidobacterium longum NBM7–1 (CKD1) with anti-diabetic medicines, LobeglitazoneⓇ (LO), SitagliptinⓇ (...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Won Jun Kim, Bum Ju Kil, Chaewon Lee, Tae Young Kim, Goeun Han, Yukyung Choi, Kyunghwan Kim, Chang Hun Shin, Seung-Young Park, Heebal Kim, Myunghoo Kim, Chul Sung Huh
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Taylor & Francis Group 2024-12-01
סדרה:	Gut Microbes
נושאים:	Bifidobacterium longum CKD1 anti-diabetic medicines IL-22 signaling insulin resistance hepatic steatosis
גישה מקוונת:	https://www.tandfonline.com/doi/10.1080/19490976.2024.2319889
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!